肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

新型肿瘤免疫疫苗NBS20，甚至比PD1抗体有更强的治疗作用

2015-05-09 MedSci MedSci原创

NBS20PD1
关注

NeoStem启动了“患者特异性靶向免疫治疗候选药物”eltrapuldencel-T（这个长长的名字就够NB了，所以产品编号叫NBS20）3期复发或4期转移性黑色素瘤的三期临床实验。该药物获得FDA特殊试验方案评价（Special Protocol Assessment）、快车道地位（Fast Track Designation）、孤儿药（Orphan Drug）、EMA认定的“Advance

NeoStem启动了“患者特异性靶向免疫治疗候选药物”eltrapuldencel-T（这个长长的名字就够NB了，所以产品编号叫NBS20）3期复发或4期转移性黑色素瘤的三期临床实验。该药物获得FDA特殊试验方案评价（Special Protocol Assessment）、快车道地位（Fast Track Designation）、孤儿药（Orphan Drug）、EMA认定的“Advanced Therapy Medicinal Product” 。

这是NeoStem改善恶性黑色素瘤的临床数据：

这么牛的治疗方案到底是怎么做的呢？其实这么震撼的治疗效果就是一种DC疫苗，你想说Dendron的Provenge？别急，非常之疗效，必有非常之方法：首先获得患者的肿瘤样本，分离肿瘤干细胞，体外扩增，照射灭活，与体外培养的单核细胞来源的DC细胞混合培养两周—搞定！

对了，记得要加GM-CSF（当然没有这么简单，更多细节自己看文献吧）

我们再来看下临床数据：


上述数据对恶性黑色素瘤的治疗效果是空前的。

原始出处：

Dillman RO1.Cancer vaccines: can they improve survival? Cancer Biother Radiopharm. 2015 May;30(4):147-51.


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2086594, encodeId=19f7208659452, content=<a href='/topic/show?id=913612563de' target=_blank style='color:#2F92EE;'>#NBS20#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12563, encryptionId=913612563de, topicName=NBS20)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jul 20 15:54:00 CST 2015, time=2015-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23471, encodeId=6d70234e1bf, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 13 21:28:00 CST 2015, time=2015-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23077, encodeId=55f8230e750, content=谢谢，资源很丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Sun May 10 01:19:00 CST 2015, time=2015-05-10, status=1, ipAttribution=)]
    2015-07-20 智智灵药

    #NBS20#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2086594, encodeId=19f7208659452, content=<a href='/topic/show?id=913612563de' target=_blank style='color:#2F92EE;'>#NBS20#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12563, encryptionId=913612563de, topicName=NBS20)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jul 20 15:54:00 CST 2015, time=2015-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23471, encodeId=6d70234e1bf, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 13 21:28:00 CST 2015, time=2015-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23077, encodeId=55f8230e750, content=谢谢，资源很丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Sun May 10 01:19:00 CST 2015, time=2015-05-10, status=1, ipAttribution=)]
    2015-05-13 huaxipanxing

    看看

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2086594, encodeId=19f7208659452, content=<a href='/topic/show?id=913612563de' target=_blank style='color:#2F92EE;'>#NBS20#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12563, encryptionId=913612563de, topicName=NBS20)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon Jul 20 15:54:00 CST 2015, time=2015-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23471, encodeId=6d70234e1bf, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed May 13 21:28:00 CST 2015, time=2015-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23077, encodeId=55f8230e750, content=谢谢，资源很丰富, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Sun May 10 01:19:00 CST 2015, time=2015-05-10, status=1, ipAttribution=)]
    2015-05-10 zhouanxiu

    谢谢，资源很丰富

    0